Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?

The article focuses on treatment of severe eosinophilic asthma with anti-interleukin-5 antibodies. Studies with one of the first antibodies against interleukin 5, mepolizumab led to interest in the development of other anti-interleukin-5 pathway therapies, reslizumab and benralizumab. The use of mepolizumab and reslizumab in a severe eosinophilic asthma phenotype with history of exacerbations has shown reductions in asthma exacerbations.